The organs-on-a-chip technology has shown strong promise in mimicking the complexity of native tissues in vitro and ex vivo, and recently significant advances have been made in applying this technology to studies of the kidney and its diseases. Individual components of the nephron, including the glomerulus, proximal tubule, and distal tubule/medullary collecting duct, have been successfully mimicked using organs-on-a-chip technology and yielding strong promises in advancing the field of ex vivo drug toxicity testing and augmenting renal replacement therapies. Although these models show promise over 2-dimensional cell systems in recapitulating important nephron features in vitro, nephron functions, such as tubular secretion, intracellular metabolism, and renin and vitamin D production, as well as prostaglandin synthesis are still poorly recapitulated in on-chip models. Moreover, construction of multiple-renal-components-ona-chip models, in which various structures and cells of the renal system interact with each other, has remained a challenge. Overall, on-chip models show promise in advancing models of normal and pathological renal physiology, in predicting nephrotoxicity, and in advancing treatment of chronic kidney diseases.
U sing technology partially evolved from the bioreactor industry 1 and adapted for tissue engineering, organon-a-chip technology has recently been created by culturing cells in microchannels and microfluidic systems, thus recapitulating important tissue-and organ-level functions in vitro and ex vivo. The addition of living renal proximal tubular cells to microchannels or hollow dialysis fibers improves waste excretion, glucose reabsorption, and middlesized molecule clearance. 2 Metabolic and endocrine functions may be improved by culture of primary renal epithelial cell types found in normal renal tissue, 2, 3 and the use of flow in microfluidic systems recapitulates the renal tubular microenvironment ex vivo, stimulating cell polarization and augmenting function. 4 To date, cell-based microphysiological systems have been applied to developing models of renal physiology, pathophysiology, and tissue pathology. These models may also be applied to testing drugs and chemicals for nephrotoxicity, circumventing limitations of 2-dimensional (2D) cell culture systems [5] [6] [7] and animal models 5 ( Figure 1 ). In series with other organ-on-a-chip platforms, these models show promise in studies of systemic disease and secondary drug toxicities. mechanics influence cell differentiation and function, and coculture of varying cell types mimics the diversity and complexity of native tissues, overcoming limitations of conventional single cell type-dependent in vitro models. Several organ-on-a-chip devices can subsequently be linked to produce multi-organ-on-a-chip and body-or human-on-a-chip systems to investigate their interactions. 10, 21, 22 Cells used for microphysiological systems. Immortalized cell lines are most commonly used in developing cell-based microphysiological systems. These lines include canine (Madin-Darby canine kidney [MDCK] ) tubular epithelial cells, [23] [24] [25] porcine (Lilly Laboratories cell porcine kidney 1) tubular epithelial cells, 26 opossum (opossum kidney) proximal tubular epithelial cells, 27, 28 and human (human kidney-2) proximal tubular epithelial cells. 29 Unfortunately, none of these cell lines fully recapitulate the primary cell phenotype, 6 nor do they display functional differentiation. 7 The continued growth of immortalized cells may lead to blockage of hollow fibers, 26 and species-dependent variations in tubular function may limit the usefulness of animal-derived cell lines in human disease models and therapeutic screening.
Primary human cells, such as human proximal tubule (PT) epithelial cells (hPTECs), 30 circumvent these problems and are often used in in vitro models. However, it is often difficult to obtain sufficient numbers of primary PT cells that have a limited number of population doublings (a maximum of w12 doublings).
2 By using antisense nucleotides or RNA interference (small interfering RNA transfected to the tumor suppressor p53 or the cyclin-dependent kinase inhibitor p16INK4a), human PT cell doublings can be increased by 3-to 5-fold. 2 When seeded into hollow fibers, these small interfering RNA-transfected cells form a confluent layer of cells that covered the inner surface of the hollow fibers within 1 week and well-developed microvilli were visible on the apical side of these cells. In comparison with membranes lacking this primary cell lining, leakage of creatinine and urea nitrogen decreases while water, sodium, and glucose reabsorption increase in PT cell-lined fibers.
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Embryonic stem cell-derived hPTEC-like cells are also promising but have not, to date, been sufficiently characterized in microfluidic systems. 30 More recently, induced pluripotent stem cells (iPSCs) have been explored as a continuous source of primary cells. Musah et al. used human iPSC-derived terminally differentiated podocytes to successfully develop a glomerulus-on-a-chip.
14,31,32 CRISPR-mutant kidney organoids 33 have also shown promise in disease models and drug development studies.
Structural materials used in organ-on-a-chip systems.
Polydimethylsiloxane (PDMS) is a common material used for the fabrication of microfluidic devices, which combines the advantages of a long shelf life, excellent hemo-and biocompatibility profiles, high gas permeability, high chemical sensitivity, and transparency in a low-cost product. 34, 35 However, PDMS absorbs hydrophobic compounds, limiting its application in microfluidic devices used for drug testing. [36] [37] [38] Thermoplastic materials composed of polycarbonate, polystyrene, and poly(methyl methacrylate), all of which have low absorption of hydrophobic compounds, are thus often preferred in biochips. 39 Various natural and synthetic polymer-based hydrogels may be added to both PDMS-and non-PDMS-based microfluidic devices, allowing them to better mimic natural physiological scaffolds. 40 The first such successful scaffold was developed when Ng et al., which demonstrated that hollow fibers containing an inner hydrogel core coated with fibrin displayed enhanced formation of hPTEC monolayers and increased fluid resorption from microchannels. 41 Microsensors may be embedded in bioengineered scaffolds, improving real-time assessment of glomerular and tubular physiology in response to environmental changes. Ferrel et al. developed a microfluidic bioreactor from polycarbonate membranes coated with type IV collagen and seeded with human renal epithelial cells and MDCK cells. These bioreactors contained integrated electrodes for the measurement of transepithelial electrical resistance, renal epithelial cell growth, and the integrity of tight junctions. 24 After a disruption in tight junctions, a decrease in transepithelial electrical resistance was noted, correlating with a change in the transport of inulin, which was used as a tracer in these studies. Later, renal tubule epithelial cells (opossum kidney cell line) were cultured in this microfluidic bioreactor to investigate the effects of shear stress on albumin handling. 27, 28 The finding that increased albumin uptake and/or degradation by renal cells associated with shear stress in this study suggested that embedded microsensors could be a useful monitoring device in microfluidic systems.
Models of kidney physiology and pathophysiology. Multiple cell types and functional units comprise the human kidney. Thus, to be physiologically relevant, a biomimetic kidney-ona-chip must integrate cell-cell interactions, such as those that exist between glomerular vascular endothelial cells and podocytes, transcellular electrochemical and osmotic pressure gradients, structural arrangement of renal tubular segments, fluid flow dynamics, and cellular metabolic and endocrine functions. To date, models of glomerular, proximal tubular, and distal tubular physiology have been developed using onchip technology ( Table 1 ). The integration of these components in the development of a true kidney-on-a-chip 50 has yet to be achieved ( Figure 2) .
Glomerulus on-a-chip. The development of a functional glomerulus-on-a-chip was stymied by a lack of functional 
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PTECs and fibroblasts Development of a 3D-bioprinted PCT-on-a-chip 3D PTs on a chip exhibit enhanced epithelial morphology and functional properties. Upon introducing cyclosporine A, the epithelial barrier was disrupted in a dose-dependent manner 3D bioprinting of the PCT Homan et al. (Figure 2f ) in a system with separate microfluidic channels mimicking urinary and blood flow. Production of basement membrane collagen and a tissue-tissue interface were observed as was a physiological differential clearance of albumin and inulin. Adriamycincaused podocyte disruption, loss of function, and cell death in this system mimicking the toxicity of Adriamycin in vivo were observed.
Zhou et al. used the glomerulus-on-a-chip concept to develop a model of hypertensive glomerulopathy. 49 Using conditionally immortalized glomerular endothelial cells and mouse podocyte precursor (mouse podocyte clone 5) cells, 2 microfluidic channels were lined by closely approximated layers of glomerular endothelial cells and podocytes. Fluid flow in the channels affected cytoskeletal rearrangement in the adjacent cells, resulting in cellular damage and glomerular leakage. Wang et al. 52 subsequently reported the use of a glomerulus-on-a-chip microdevice for studying early-stage diabetic nephropathy, providing further proof of principle that these devices could serve as disease models of glomerulopathy.
PT-on-a-chip. Several investigators have successfully cultured renal proximal tubular cells in tunable hollow fibers, providing immunoprotection during extracapillary blood flow. Ng et al. seeded hPTECs on the inner surface of fibers composed of fibrin-coated hydrogel and noted the successful formation of a monolayer that had an enormous transport potential for glucose (Figure 3) . 41 Jang et al. cultured hPTECs on microchannels composed of collagen type IV-coated polyester membranes. 7 Compared to control systems not exposed to fluid shear stress, tubular cells in microfluidic systems regained normal columnar shape, polarity, and primary cilia. They also displayed an increase in cellular uptake of albumin and an increased recovery from cisplatin-induced damage. 7 Sciancalepore et al. cultured human renal progenitor cells (hPCs) on porous polycarbonate membranes coated with either fibronectin, laminin, or Matrigel that separated PDMS microchannels. 44 In this study, fibronectin was associated with the highest number of metabolically active cells ( Figure 2c ) and flow shear stress-induced polarization of cultured cells. Jansen et al. 46 developed functional renal tubules by using hPTEC-biofunctionalized hollow fibers and demonstrated secretory clearance of albumin-bound uremic toxins and albumin reabsorption across the tubule. microfluidic chamber filled with the extracellular matrix surrounding tubular channels and noted excellent cell viability (>95%) for up to 4 weeks in culture. 45 Importantly, these cells produced a collagen matrix, formed tubular structures, and maintained renal epithelial differentiation, morphology, and polarization. They also showed evidence of ammoniagenesis and vitamin D activation, thus demonstrating, for the first time, basolateral solute transport, apical solute uptake, and intracellular enzymatic function. Microfluidic systems thus appear to mimic physiological conditions and maintain PT cells in a more differentiated state in vitro than do conventional culture systems.
Recent advances in 3-dimensional (3D) bioprinting have allowed the development of increasingly complex structures. Homan et al. printed a fugitive pluronic ink on a gelatinfibrinogen extracellular matrix and cast an additional extracellular matrix hydrogel around the bioprinted material. 12 Convoluted microchannels were created in the hydrogel by evacuating the pluronic ink and seeded with hPTECs (hPTEC-TERT1 cell line). Perfused cells in this system demonstrated greater albumin uptake and morphological properties more similar to human proximal tubular cells than did cells in classical 2D culture systems (Figure 2d ). In this study, system functionality was maintained for >2 months, suggesting that bioprinting may allow the creation of increasingly complex structures with improved cellular functionality and longevity.
Distal tubule-/collecting duct-on-a-chip. In contrast to PT cells, few studies have examined the physiology of distal tubular and cortical collecting duct cells cultured on biomimetic platforms. In 2007, Baudoin et al. developed a microchip by using fibronectin-coated microchannels in a PDMS device. MDCK (distal tubular) cells were cultured in microchannels. These cells were able to attach, proliferate, and form 3D tissue-like structures covering the microchannels (Figure 2e) . However, fluid rates of 50 ml/min resulted in impaired cell proliferation and increased cell death in this system, suggesting that MDCK cells are not accustomed to the flow rates observed in the PT. 13 In 2010, Jang and Suh cultured primary rat renal collecting duct cells on a multilayer microfluidic device created from thin fibronectincoated porous polyster membranes situated in a PDMS microchamber. 4 Shear stress was maintained at 1 dyn/cm 2 (0.1 Pa) by accounting for fluid flow rates, viscosity, and channel size in this system. At this stress level, cytoskeletal rearrangement, number of cell junctions, and cell polarity increased. Higher and denser cell monolayers were formed in collagen hollow fibers as compared with thinner, less dense cells in monolayers formed on flat collagen membranes. In addition to morphological changes, cells in this system displayed an increased capacity for sodium and water transport and an increased expression of brush border enzymes of alkaline phosphatase and g-glutamyltransferase (Figure 3) . 27, 28 Cell functionality was related to fiber diameter, with smaller-diameter fibers resulting in increasingly functional cells (normal renal tubules have a small diameter of w50 mm
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). These findings suggested that cells could sense structural and spatial cues and that surface curvature might have a positive effect on distal tubular cell function. 27, 28, 54 They further suggested that a diameter of 50 mm (i.e., the size of native renal tubules) should be used in bioengineered distal tubules to mimic the size of native tubules and result in optimal functionality.
Toward kidney-on-a-chip. In 2008, Weinberg et al. proposed a design for replicating a nephron, with a system containing 4 parts: glomerulus, PT, loop of Henle, and connector ( Figure 2a) . 50 To date, the PT has been best studied in model systems; early work on glomerular and distal tubule physiology is promising. However, other portions of the nephron, including the thick ascending limb, the interstitium, and the cortical collecting duct, have been less well-characterized in vitro. In addition, the structuralfunctional arrangements of different nephron segments, the specialized structures resulting from these arrangements, the physiology of countercurrent exchange, and the diffusion of nutrients, waste, hormones, and drugs through the interstitium of the native kidney 22 make the development of a functional kidney-on-a-chip more than just the sum of individual nephron components. Although higher-order structures have not yet been modeled in vitro, new developments hold promise for surmounting some of these challenges. In 2013, Mu et al. cultured MDCK renal epithelial cells and primary human umbilical vein endothelial cells on opposite sides of an alginate-collagen type I composite hydrogel in a microtubular 3D system (Figure 2b) . 23 This organization represented the first step toward creating a system that mimics the interaction between blood vessels and tubular cells, as occurs in the juxtaglomerular apparatus and in countercurrent exchange. Moreover, current technologies allow the creation of 41 To optimize viewing of this image, please see the online version of this article at www.kidney-international.org. (2018) -, --- chemical, oxygen, and nutritional gradients in on-chip platforms and current data suggest that efficient chemotaxis can be achieved with much shallower gradients in these systems than was previously achieved with 2D in vitro systems. 22 Thus, more complex physiological in vitro systems of renal physiology may be on the horizon.
Clinical applications
Drug development and testing. New drugs must be evaluated for efficacy and safety before clinical use, and preliminary tests for nephrotoxicity are typically performed in animals. However, animal studies are expensive and slow. They are often species-specific, failing to predict human nephrotoxicity; and they are often associated with ethical concerns. 5, 55 The in vitro use of cell lines avoids ethical concerns; however, many cell lines are derived from animals and both human-and animal-derived immortalized cell lines do not fully recapitulate the structure and function of their native counterparts. As a result, nephrotoxicity is often not discovered until testing is initiated in humans and many cases of nephrotoxicity are not identified until phase III and phase IV trials. 56, 57 Because of their high energy needs, PT cells are particularly susceptible to drug toxicity, 7, 58, 59 making the development of in vitro models of proximal tubular function attractive to drug developers. High resorption and molecule transport rates allow drugs and chemicals to accumulate in PT cells and in the intercellular space. 12 Multiple 2D PT cell culture models have been useful in defining the nephrotoxic pathophysiology of drugs such as cisplatin, which accumulate in proximal tubular cells. 60, 61 These models have also been useful in studying cimetidine-mediated recovery from cisplatininduced proximal tubular dysfunction. 7 However, 2D cell culture models fail to identify toxicity of drugs and chemicals with flow-dependent tubular actions. In an attempt to more faithfully recapitulate in vivo physiology, multicellular systems including static 3D culture and organoid models were developed. Unfortunately, organoids lack accessible inlets and outlets, limiting their usefulness 12 and static 3D culture models lack natural flow dynamics necessary for the development of cell polarity and function. 4 Recent attention has thus been directed to integrating microfluidic technology 62 into 3D models. In one study aimed at developing a reliable cell-based nephrotoxicity screening system, primary hPTECs were cultured on tubules embedded in type I collagen. 29 In this system, heme oxygenase-1 RNA and protein expression in cell lysates were found to be sensitive and specific markers of nephrotoxicity. In a bioprinted system of the human PT, PTEC-TERT1 cells exposed to cyclosporine A demonstrated a dose-dependent disruption in function, suggesting that this system could also be used for qualitative and quantitative studies of drug-induced proximal tubular dysfunction. 12 Drugs that disturb renal blood flow have traditionally proved challenging for in vitro nephrotoxicity screens. Vasoconstrictors such as catecholamines and calcineurin inhibitors reduce oxygen delivery, resulting in injury to the renal medulla. 63, 64 However, recently developed blood vesselon-a-chip devices 65 have demonstrated that vasoconstrictive behaviors can be evaluated in organ-on-chip models, raising the possibility that on-chip models might soon be available to model vasoconstrictive nephrotoxicity.
Evaluation of many types of toxicities in vitro requires systems to integrate multiple cell types from different organs, 66 which can help to evaluate systemic 10 and secondary drug toxicities resulting from drug metabolism 11 and to evaluate inflammatory responses that may not always be detected during direct testing of the drug on the target organ. In 2017, Vernetti et al. combined on-chip systems representing absorption (human jejunal enteroids), metabolism (primary human hepatocytes), and clearance (primary human proximal tubular epithelial cells) with skeletal muscle (primary human myocytes) and neurovascular (iPSC-derived human neurons and astrocytes) models, in which media were transferred sequentially from one organ to the other. 47 Multiorgan-on-a-chip models comprising intestine (primary human small intestinal epithelial cells), liver (primary human hepatic stellate cells combined with immortalized HepaRG cells), skin (human biopsy tissue), and human renal PT cell line (RPTEC/TERT1) were similarly developed by Maschmeyer et al. 67 to assess drug absorption, distribution, metabolism, and excretion as well as multiorgan toxicity. Li et al. further developed a system that linked intestine colorectal adenocarcinoma cell line with rat primary glomerular endothelial cells in a compartmentalized microchamber of the microfluidic system. 48 When tested for digoxin, this system demonstrated that digoxin induced glomerular endothelial toxicity, manifested by increased permeability and cell death, consistent with clinical digoxin nephrotoxicity.
In sum, present data suggest that on-chip systems may be useful tools for predicting in vivo proximal tubular toxicity. Recent advances in modeling vascular systems hold promise for vasoconstrictive nephropathy screening and multi-organon-a-chip models hold promise for improving prediction of secondary toxicities. However, on-chip technologies for testing distal tubular drug toxicities (as occurs with medications such as amphotericin), tubular obstruction (i.e., acyclovir toxicity), and interstitial nephritis (as occurs with medications such as nonsteroidal anti-inflammatory drugs and cephalosporins) remain limited.
Renal replacement therapies. In addition to microscopic on-chip technologies, the integration of cells with microfluidics has therapeutic potential at macroscale. Although lifesustaining for many, current hemodialysis therapies offer only a primitive approximation of renal function and mortality rates in dialysis have not changed in decades. In contrast to the functioning nephron, in which toxins are filtered and secreted while vital electrolytes and small molecules are reabsorbed, clearance of small-and mid-sized molecules by hemodialysis relies on 1-way diffusion and/or convection across a relatively nonselective semipermeable membrane. Efforts have been made to modify traditional dialysis filters to more accurately approximate true nephron function. MacKay 3 Subsequently, KaazempurMofrad et al. suggested that PT cells might be combined with microelectromechanical systems in hemodialysis systems to allow electrolyte and small-and mid-sized molecule reabsorption and secretion. 51 Useful molecules that may escape during dialysis conducted with current methods may thus be reabsorbed by PT cells in these hybrid systems. A renal tubule assist device (RAD) was subsequently developed for use with continuous venovenous hemofiltration (Figure 4a) . RAD was associated with improved survival in an animal model of septic shock, 70 and an initial phase II multicenter study suggested a survival advantage of RAD over conventional hemofiltration. 68 Although a subsequent clinical trial of 134 patients with acute kidney injury in the intensive care unit randomized to continuous renal replacement therapy alone or to continuous renal replacement therapy and RAD showed no overall benefit of RAD, 71 a subgroup analysis demonstrated lower mortality rates in patients with a postfilter ionized calcium level of #0.4 mmol/l who received RAD compared to conventional continuous renal replacement therapy. Although these initial results appeared promising for improving outcomes in certain clinical settings, advances in RAD technology have been hindered by slow production rates and by expensive and delicate storage requirements. 69, 70 New designs and manufacturing techniques, including the development of niobium-coated carbon disks housed in a perfusable polycarbonate chamber and seeded with human epithelial cells (Figure 4b ), will enable simplified and increased production rates. 69 Limitations in cell sourcing (i.e., maintaining primary cells in adequate numbers and for sufficient times without reverting to progenitor cells) may in future be addressed by using patient-derived iPSCs and/or allogenic cells that are immune evasive from the extracorporeal circuit. 69 Opportunities and challenges. The use of microfluidic systems allows coculture of different cell types, which is essential for studying cell-cell interactions, signaling, and cell recruitment in both health and disease states. 8 Moreover, the ability to integrate sensors into microfluidic systems 72, 73 permits continuous measurement of cellular behavior. 74 In addition to the use of electrodes in monitoring epithelial barrier integrity through transepithelial electrical resistance, 75 the integration of mass spectrometric analysis to on-chip platforms 76 allows the analysis of genetic, proteomic, and metabolomic signatures in response to specific compounds and stimuli. 8, 77 Linking on-chip systems with data communication tools is anticipated to further improve cellular monitoring as well as prediction of toxicity models. Moreover, although animalderived cell lines with poor translation to human physiology have been traditionally used in microfluidic models, iPSC-derived cells from humans have been increasingly used in recent years to model terminally differentiated human cells. Combining stimuli-responsive materials 78, 79 and biosensors 80 with advances in stem cell biology in deriving and propagating terminally different cell types 14 is predicted to further improve the ability of on-chip technology to provide useful models of renal physiology, renal disease, and drug toxicity screening.
However, several challenges persist in the pursuit of true kidney-on-a-chip devices. One major obstacle is the limited life span of cells in these devices. 81 This limitation is particularly acute when primary-as opposed to immortalizedcells are used in on-chip systems. The appropriateness of current cell lines in faithfully mimicking in vivo biology also limits the application of these model systems. To date, all onchip systems of drug toxicity have been hampered by inadequate in vitro modeling of tubular drug transporters and metabolic enzymes. Current models only partially reproduce normal physiology. Furthermore, challenges persist in optimizing biomaterials used in microfluidic systems. For clinical use, these materials need to be biocompatible, inert (so as not to absorb chemicals), and nonleaching (to avoid interference of compounds from the material itself). 8 Thus, although preliminary data suggest that integrated systems can be used to assess drug absorption, distribution, metabolism, and excretion characteristics in vitro, system validation, design standardization, and integration with standard laboratory tools will be essential before these systems can be used on a large scale. 8 To date, no single on-chip system has gained widespread acceptance, and all are limited by a lack of tissuetissue interactions and lack of integration with lymphatic and nervous systems. As a result, reliable extrapolation of drug toxicity data obtained from in vitro testing to in vivo biology remains limited. 9 Advances in engineering and cell biology already provide potential solutions to these limitations. Microfluidics-based systems allow the precise control of cell microenvironments in both space and time 82 and also allow the direct delivery of therapeutics to cells (i.e., stem cell transfection with modified mRNA). 83 In turn, advances in stem cell technology, such as those that have been demonstrated in the integration of iPSCderived podocytes into microfluidic devices, 14 have helped to overcome limitations of modeling terminally differentiated cell types in vitro. The 3D bioprinting technology enables precise production of complex and multiplexed structures 84, 85 and ensures reproducibility in manufacturing. 86 The use of nanotechnology will further improve precision at the level of cellular diagnosis and therapy. Recently, 4-dimensional bioprinting has been developed [87] [88] [89] in which biomimetic and dynamic 88 tissues can potentially be integrated into microfluidic platforms.
To date, disease models have been developed with the help of microfluidics in several organ systems, offering promise that on-chip models may, in the future, be used to study kidney-specific diseases. In 2015, Huh developed a lung-on-achip in which alveolar epithelial cell and pulmonary microvascular endothelial cells culture on opposite sides of a 10-mm microporous membrane. In this model, interleukin-2 induced vascular leakage, providing a novel in vitro model of chemotherapy-induced pulmonary edema 90 that could be useful in developing models of renal basement membrane permeability, such as that occurs in diabetic nephropathy or nephrotic syndrome. More recently, Banaeiyan et al. observed 3D tissue-like structures and bile canaliculi network formation when coculturing human hepatocellular carcinoma cell line (HepG2) with human iPSC-derived hepatocytes in hexagonal chambers. Albumin secretion and urea synthesis were observed in the microfluidic devices of this liver-on-a-chip model, demonstrating that structural configuration and exposure to continuous fluid flow increase cell functionality. 91 The effects of physiological and pathological strain on vascular aging have been evaluated in an on-chip model of Hutchinson-Gilford progeria syndrome in which patientspecific iPSC-derived endothelial cells were cultured in microfluidic systems. 92 The effective use of these iPCSderived cells in microfluidic systems suggest that patientspecific genetic renal disease (i.e., Alport syndrome and cystic kidney diseases) may, in future, be successfully modeled in vitro. Finally, the bioprinted vascular endothelium has recently been used to study the physiology and pathophysiology of thrombosis 93 and tunable microfluidic structures that allow the antibody capture and release of circulating tumor cells have been used in cancer research. 94, 95 These improved printing technologies and advanced materials hold promise for the future of studying the role of vascular damage and immune-mediated disease in conditions such as hemolytic uremic syndrome/thrombotic microangiopathy and of evaluating the mechanisms of renal transplantation rejection and tolerance.
Conclusions
Over the last 20 years, research in bioengineered materials and microfluidics, starting with the development of renal cellseeded hollow fiber systems and progressing to models representing more diverse kidney functions, has led to the development of on-chip platforms that may prove useful adjuncts to predicting drug toxicity and to modeling of human kidney disease in vitro. It is hoped that many patients may be saved from the morbidity and mortality associated with unpredicted adverse drug reactions and drug development costs may be substantially reduced. It is hoped that these technologies will facilitate research into the pathogenesis and treatment of renal diseases that contribute to considerable human and societal costs worldwide.
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